Immunohistochemical expression of estrogen and progesterone receptors in endometrial polyps: A comparison between benign and malignant polyps in postmenopausal patients

Antunes,Armando; Vassallo,José; Pinheiro,Anderson; Leão,Rogério; Pinto Neto,Aarão Mendes; Costa‑Paiva,Lucia

doi:10.3892/ol.2014.2004

Immunohistochemical expression of estrogen and progesterone receptors in endometrial polyps: A comparison between benign and malignant polyps in postmenopausal patients

Authors:
- Armando Antunes
- José Vassallo
- Anderson Pinheiro
- Rogério Leão
- Aarão Mendes Pinto Neto
- Lucia Costa‑Paiva
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, State University of Campinas School of Medicine, Campinas, São Paulo 13.083‑881, Brazil, Department of Anatomical Pathology, State University of Campinas School of Medicine, Campinas, São Paulo 13.083‑881, Brazil
Published online on: March 28, 2014 https://doi.org/10.3892/ol.2014.2004
Pages: 1944-1950

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to evaluate estrogen receptor (ER) and progesterone receptor (PR) expression in the glandular epithelium and stroma of benign and malignant endometrial polyps of postmenopausal patients. A total of 1,050 females underwent surgical hysteroscopy at the Professor Dr José Aristodemo Pinotti Women's Hospital, Center for Integral Attention to Women's Health of the State University of Campinas, between January 1998 and December 2008. Of the total number, 390 postmenopausal females with endometrial polyps were included in the study. Polypoid lesions were histologically classified as benign lesions (endometrial polyps and polyps with non‑atypical simple hyperplasia or non‑atypical complex hyperplasia) and premalignant and malignant lesions (polyps with atypical simple hyperplasia or atypical complex hyperplasia and carcinomatous polyps). ER and PR expression was evaluated by immunohistochemistry according to cell staining, intensity of nuclear staining and final score. The final score for receptor expression was compared between the benign and premalignant/malignant polyps. The prevalence of malignancy in endometrial polyps was 7.1% and was associated with postmenopausal bleeding. Only the final score for ER expression in the stroma of endometrial polyps was higher in the benign group than in the premalignant/malignant group, and this difference was significant. However, no difference was identified in PR expression. In addition, the risk of malignancy in endometrial polyps was significantly higher when the expression of ER and PR was negative in the stromal component of the polyp (P<0.01). The malignancy of endometrial polyps was also associated with a low expression of stromal ER, however, PR expression did not show any association with the risk of malignancy.

View Figures

View References

1	Kurman RL: Blaustein’s Pathology of the Female Genital Tract. 5th edition. Springer; New York: pp. 448–450. 2002
2	Haimov-Kochman R, Deri-Hasid R, Hamani Y and Voss E: The natural course of endometrial polyps: Could they vanish when left untreated? Fert Steril. 92:8282009. View Article : Google Scholar : PubMed/NCBI
3	Dreisler E, Stampe SS, Ibsen PH and Lose G: Prevalence of endometrial polyps and abnormal uterine bleeding in a Danish population aged 20–74 years. Ultrasound Obstet Gynecol. 33:102–108. 2009.
4	Lee SC, Kaunitz AM, Ramos LS and Rhatigan RM: The oncogenic potential of endometrial polyps. A Systematic Review and Meta-Analysis. Obstet Gynecol. 116:1197–1205. 2010. View Article : Google Scholar : PubMed/NCBI
5	Antunes A Jr, Costa-Paiva L, Arthuso M, Costa JV and Pinto-Neto AM: Endometrial polyps in pre- and postmenopausal women: factors associated with malignancy. Maturitas. 57:415–421. 2007. View Article : Google Scholar : PubMed/NCBI
6	Oguz S, Sargin A, KeleKei S, Aytan H, Tapisiz OL and Mollamahmutoglu L: The role of hormone replacement therapy in endometrial polyp formation. Maturitas. 50:231–236. 2005. View Article : Google Scholar : PubMed/NCBI
7	Lopes RG, Baracat EC, de Albuquerque Neto LC, et al: Analysis of estrogen- and progesterone-receptor expression in endometrial polyps. J Minim Invasive Gynecol. 14:300–303. 2007. View Article : Google Scholar : PubMed/NCBI
8	Almeida ECS, Nogueira AA, Reis FJC, Ramalho LNZ and Zucoloto S: Immunohistochemical expression of estrogen and progesterone receptors in endometrial polyps and adjacent endometrium in postmenopausal women. Maturitas. 49:229–233. 2004. View Article : Google Scholar : PubMed/NCBI
9	Inceboz US, Nese N, Uyar Y, Ozcakir HT, Kurtul O, Baytur YB, et al: Hormone receptor expressions and proliferation markers in postmenopausal endometrial polyps. Gynecol Obstet Invest. 61:24–28. 2006. View Article : Google Scholar : PubMed/NCBI
10	Gul A, Ugur M, Iskender C, Zulfikaroglu E and Ozaksit G: Immunohistochemical expression of estrogen and progesterone receptors in endometrial polyps and its relationship to clinical parameters. Arch Gynecol Obstet. 281:479–483. 2010. View Article : Google Scholar : PubMed/NCBI
11	Fons G, Hasibuan SM, van der Velden J and ten Kate FJ: Validation of tissue microarray technology in endometrioid cancer of the endometrium. J Clin Pathol. 60:500–503. 2007. View Article : Google Scholar : PubMed/NCBI
12	Harvey JM, Clark GM, Osbome CK and Allred DC: Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 17:1474–1481. 1999.
13	Costa-Paiva L, Godoy CE Jr, Antunes A Jr, Caseiro JD, Arthuso M and Pinto-Neto AM: Risk of malignancy in endometrial polyps in premenopausal and postmenopausal women according to clinicopathologic characteristics. Menopause. 18:1–5. 2011. View Article : Google Scholar
14	Anastasiadis PG, Koutlaki NG, Skaphida PG, Galazios GC, Tsikouras PN and Liberis VA: Endometrial polyps: prevalence, detection, and malignant potential in women with abnormal uterine bleeding. Eur J Gynaecol Oncol. 21:180–183. 2000.PubMed/NCBI
15	Martinez MA, Jou P, Nonell R, Cardona M, Alonso I and Vanrell JA: Endometrial polyps: risk of malignancy and clinical-anatomical correlation. Prog Obstet Ginecol. 47:506–510. 2004.
16	Speroff L: The estrogen receptor: changing concepts. Clinical lessons from molecular biology. Reproductive Medicine - A Millennium Review. Coutinho EM and Spinola P: Parthenon Publishing Group; New York: pp. 155–161. 1999
17	Yen SSC: Human menstrual cycle. Reproductive Endocrinology: Physiology, Pathophysiology, and Clinical Management. Yen SSC, Jaffe RB and Barbieri RL: Saunders; Philadelphia: pp. 193–227. 1999
18	Longcope C and Baker S: Androgen and estrogen dynamics: relationships with age, weight and menopausal status. J Clin Endocrinol Metabol. 76:601–604. 1993.PubMed/NCBI
19	McGurgan P, Taylor LJ, Duffy SR and O’Donovan PJ: Are endometrial polyps from pre-menopausal women similar to post-menopausal women? An immunohistochemical comparison of endometrial polyps from pre- and post-menopausal women. Maturitas. 54:277–284. 2006. View Article : Google Scholar : PubMed/NCBI
20	Pickartz H, Beckmann R, Fleige B, Due W, Gerdes J and Stein H: Steroid receptors and proliferative activity in non-neoplastic and neoplastic endometria. Virchows Arch A: Pathol Anat Histopathol. 417:163–171. 1990. View Article : Google Scholar : PubMed/NCBI
21	Giuffre G, Arena F, Scarfi R, Simone A, Todaro P and Tuccari G: Lactoferrin immunoexpression in endometrial carcinomas: relationships with sex steroid hormone receptors (ER and PR), proliferation indices (Ki-67 and AgNOR) and survival. Oncol Rep. 16:257–263. 2006.
22	Moshin SK, Weiss H, Havighurst T, Clark GM, Beraldo M, Roanhle D, et al: Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study. Mod Pathol. 17:1545–1554. 2004. View Article : Google Scholar : PubMed/NCBI
23	Ito K, Utsunomiya H, Yaegashi N and Sasano H: Biological roles of estrogen and progesterone in human endometrial carcinoma-new developments in potential endocrine therapy for endometrial cancer. Endocr J. 54:667–679. 2007. View Article : Google Scholar : PubMed/NCBI
24	Iversen OE, Utaaker E and Skaarland E: DNA ploidy steroid receptors as predictors of disease course in patients with endometrial carcinoma. Acta Obstet Gynecol Scand. 67:531–537. 1988. View Article : Google Scholar : PubMed/NCBI
25	Sivridis E, Giatromanolaki A, Koukourakis M and Anastasiadis P: Endometrial carcinoma: association of steroid hormone receptor expression with low angiogenesis and bcl-2 expression. Virchows Arch. 438:470–477. 2001. View Article : Google Scholar : PubMed/NCBI